x

Ncardia strategically collaborates with industry and academic partners in both public and private projects. The company has been working on a number of collaborative projects since its inception and is always interested to evaluate new opportunities.

Research Partnerships

Horizon 2020 SME Instrument

Ncardia is supported by the European Union’s Horizon 2020 research and innovation programme through an SME Instrument grant. This grant gives Ncardia the opportunity to further develop and improve its safety pharmacology assays as well as developing novel cardiac disease models and high-throughput screening assays for cardiovascular drug discovery.

Horizon 2020 Fast Track to Innovation

Three European technology SME’s, Luxcel Biosciences Ltd, Ncardia and BMG LABTECH GmbH, together with two internationally recognised research institutions, Oxford University and Imperial College London, have been awarded funding from the European commission under the H2020 Fast Track to Innovation (FTI) pilot, to develop and launch a cell metabolism analysis platform (MetaCell) that is predicted to be part of routine in vitro cell biology and drug development.

Eurostars

In HeartCHIP, supported by the Eurostars Programme, Ncardia will leverage its unique expertise in cardiac disease modeling and work in close collaboration with the German company ibidi GmbH, a leading supplier of cell-based assays, and the Erasmus University Medical Centre Rotterdam, located in The Netherlands. The partners within the HeartCHIP consortium will combine their unique proprietary technologies to develop extensive new knowledge and co-develop a breakthrough cardiac phenotypic screening platform.

FP7

Plurimes combines the expertise of eight academic and two industrial partners to bring together stem cell experts, genetic engineers, developmental biologists, cell therapy pioneers, bioengineers and specialist SMEs in a cross-disciplinary collaborative effort. PluriMes is supported through the European Commission’s Framework 7 HEALTH research programme and Coordinated by Professor Austin Smith from the Wellcome Trust – Medical Research Council Cambridge Stem Cell Institute at the University of Cambridge.

ECSEL JU

In the InForMed project an integrated pilot line for medical devices will be established, covering the complete innovation chain from technology concept to system qualification. It will include micro-fabrication, assembly and even the fabrication of smart catheters. Ncardia is active in the development of demonstrator products within the consortium, in particular demonstrator 2: Advanced devices for electrophysiology. InForMed is an ECSEL JU project and is co-funded by grants from Belgium, Finland, France, Germany, Great Britain, Ireland, the Netherlands, Spain, Sweden and Switzerland.

Crack IT InPulse

Ncardia, in a consortium with 4 academic partners and one SME, won the CRACK IT InPulse challenge for development of a cardiac contractile assay. A panel of experts from GSK, AstraZeneca, NC3Rs and renowned academic institutions selected the consortiums solutions from a strong line-up of competing technologies. The consortium will develop an assay to detect cardiac contractility effects at an early stage of drug development.

Read more: CRACK IT

CiPA

Ncardia is involved in the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative, led by the US FDA, Safety Pharmacology Society (SPS), Cardiac Safety Research Consortium (CSRC) and Health & Environmental Sciences Institute (HESI). This project aims to improve current regulatory guidances by introducing predictive technologies, including human stem cell-derived cardiomyocytes, into preclinical cardiac safety assessment. This assay, designed to assess proarrhythmic risk during new drug development, will ultimately drive the modification or replacement of the existing ICH S7A/B guidelines and elimination of E14 guidelines, virtually eliminating the need for clinical TQT studies for compounds entering clinical development.

Technology Partnerships

Ncardia is excited to work with leading technology platform providers.

Agilent Technologies

Agilent Technologies provides high performance cell analysis platforms for life science research. The xCELLigence® Real-Time Cell Analysis (RTCA) instruments and NovoCyte® flow cytometer are used in pre-clinical drug discovery and development, toxicology, safety pharmacology, and basic academic research. The xCELLigence CardioECR system is the first instrument to simultaneously monitor integrated ion channel activity, contractility and viability of cardiomyocytes enabling predictive assays for safety/toxicity assessment as well as cardiac drug discovery. Moreover, the powerful electrical pacing functionality of the CardioECR system allows for short term and chronic pacing regimens providing assessment of compounds at different beating frequencies in addition to conditioning and maturing the cardiomyocytes for assessment of inotropic compounds .

Axion BioSystems

The Maestro Pro™ and Edge™, designed by Axion BioSystems, are the world’s most powerful microelectrode array (MEA) systems. Record networks of electrically active cells (e.g. neurons, cardiac cells, and muscle cells) in a multiwell plate in real-time. Over minutes or months, gain unprecedented access to electrical network function from cultured cell populations. Perfect for characterizing hiPSC-models, researching the behavior of diseased cells, screening for drugs to treat that disease, or examining potential toxic effects of drug candidates, the Maestro platform delivers an easy-to-use, compact cellular analysis system suitable for any lab

Hamamatsu Photonics

Hamamatsu Photonics is a leading manufacturer of optoelectronics, providing solutions for a wide range of applications including drug screening and assay development. Their light sources and detectors are integrated in a wide range of high quality instrumentation used daily in laboratories across the world. You are invited to discover the FDSS (Functional Drug Screening System) screening range and its applications for research, assay development and high throughput screening. All of Hamamatsu's systems include one or multiple injection heads which can be used with different plate formats. The modularity of the systems makes each one completely unique and their adaptability ensures they will evolve with customers' changing needs.

Sophion Bioscience

Sophion Bioscience, a leader in the automated patch clamp field, helps drug discovery companies make more and better drugs, faster. Sophion provide integrated solutions for automated patch clamping and the two product families QPatch and Qube provide high-quality patch clamp data for industrial research, focused on unattended operation and ease of use, ensuring high laboratory efficiency and rapid turnaround time to results. Sophion Bioscience is headquartered in Copenhagen, Denmark and has subsidiaries in Boston, Tokyo and Shanghai, as well as distributors in Japan, India and Korea.

Nanion Technologies

Nanion Technologies is a leading provider of automated patch clamp (APC) electrophysiology systems with throughput capabilities ranging from a single cell up to fully automated high throughput screening (HTS) instruments recording from 768 cells simultaneously. Founded in 2002, Nanion has expanded its product range over the years to include in vitro systems for membrane pump and transporter recordings, bilayer recordings, and contractility measurements (impedance) from beating monolayers of cells, e.g. induced pluripotent stem cell-derived cardiac myocytes (iPSC-CMs), and confluency measurements of, e.g. hepatocytes for hepatotox screening using impedance. Nanion’s instruments combine high performance with user-friendly interfaces making them an ideal choice for academia, biotechnology, CROs and the Pharma industry.